A new study highlights how a two-drug strategy may reshape inflammatory biology in older adults newly diagnosed with acute myeloid leukemia (AML). Researchers report that azacitidine, when paired with venetoclax, is associated with measurable shifts in inflammatory markers alongside improvements in clinical response. The trial focused on elderly patients—an especially vulnerable group in AML—where both … Continue reading Azacitidine and Venetoclax Impact Inflammatory Markers and Response in Elderly AML